The company focuses on the discovery and development of drug candidates and innovative diagnostic solutions. Speaker biographies world preclinical congress europe. Combined with the relocation of our coo, dean hum, to our. Sigmaplot was also used to fit the standard curves and then. In 2019, genfit also presented positive results from our phase 2 trial in. Pdf panppar modulation effectively protects appps1. With upcoming data in both pbc and nash, were on the verge of exciting times for genfit. Dean hum on genfits quest to bring the first nash therapy to market. The investment objective of the vanguard total world stock etf seeks to track the performance of the ftse global all cap index, which covers both wellestablished and stilldeveloping markets. The scientific advisory board is chaired by professor bart staels, cofounder of genfit. The identification of naturally occurring neoruscogenin as.
Lille france, cambridge massachusetts, united states, september 26, 2019 genfit nasdaq and euronext. While nash is a much larger market, elafibranors use for another indication is certainly good news for genfit. Information obtained through genetic gain andor lossoffunction approaches is of course of great value, but it does not replace target validation through pharmacological stimulation or inhibition of a target with selective and potent chemical ligands. Its due to have the results of that study by yearend. Exact name of registrant as specified in its charter france. We show here that trep2 plays a role in the control of cell proliferation. Pdf phosphorylation of farnesoid x receptor by protein. Dean hum on genfits quest to bring the first nash therapy. Genfit reports fullyear 2019 financial results and corporate. The companies and people listed on this page at one time used the above address in association with their company. Panppar modulation effectively protects appps1 mice.
Fxr is activated by bile acids bas, such as the primary ba chenodeoxycholic acid cdca, which is the most potent ba ligand for the human fxr 2, 3. Mccaleb 3, brombacher frank 4, tobias bopp 5, hans. The francebased company said hum will relocate to its cambridge, ma, office. Genfit s scientific advisory board is made up of six members who are internationallyrecognized key opinion leaders in the field of of metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. We report here the efficacy and safety of gft505, a novel livertargeted peroxisome proliferatoractivated receptor alphadelta ppar. Genfit, hum says, focuses on metabolic diseases, which is how it got involved in the field of nash. The farnesoid x receptor fxr, nr1h4 belongs to the nuclear receptor superfamily and is activated by bile acids such as chenodeoxycholic acid, or synthetic ligands such as gw4064. Phosphorylation of farnesoid x receptor by protein kinase. Genfit, with offices in lille, france and cambridge, mass.
Matthew albert, md, phd, principal scientist, cancer immunology, genentech. Genfit is poised to become the first company to get a treatment for nash to market something that could happen as early as 2020, should its late 2019 phase iii trial results be positive. Hum, who joined genfit in 2000 as chief scientific officer will be relocating to the united states and will be based at the cambridge, m. Meanwhile, 2020 will be an important year for nash, said genfit sas ceo pascal prigent and presidentcoo dean hum, predicting the firstever drug approval with intercept pharmaceuticals inc. In addition to bas, synthetic fxr agonists have also been identified 4, 5. Yen weng 1, xiaoyu wang 1, yong ook kim 1, leonard kaps 1, yilang tang 2, olena molokanova 1, jeff r. Nr1h4 is a member of the nuclear receptor superfamily that is expressed in liver, kidney, intestine and the adrenal gland. Overview for 185 alewife brook pkwy cambridge, ma 028.
Mice were tracked using ethovision software noldus, wageningen, the netherlands. When elafibranor gets on the market about the same time as oca, the next drug will not get on the market for at least another three years, genfit chief operating officer dean hum said in an interview. List of patentees to whom patents were issued on the 16th day of july, 2019 notearranged in accordance with the first significant character or word of the name. And hum believes the positive pbc data could also provide evidence to counter those skeptics about the treatments viability for nash. Dean hum is today a key person in the organization of genfit. More than 150 global liver and metabolic disease experts issued today a call to action against the chronic liver disease nonalcoholic steatohepatitis nash, an asymptomatic, silent disease that.
There is also another program, tgftx1 that is targeting autoimmune. Our success also will depend upon our ability to attract. University of groningen causes and consequences of. The initiation of a phase ii trial of elafibranor in paediatric nash is a landmark study, as to our knowledge there has been no other molecule that has shown clinical evidence in a phase iib adult nash trial and then progressed to clinical evaluation in the paediatric nash setting. Commenting on the moves, genfit chief executive pascal prigent said. I spoke to dean hum, the current coo and cso of genfit, to find out more about the companys 20year journey and its hopes for the future. A growing nationalist and protectionist mindset around the world is creating a fresh set of challenges for global businesses. We have found 100 companies and 100 people at this address.
Vt ratings, holdings, quotes, and more etf daily news. Dean hum s appointment as president of genfit corp. The digital pathology associations annual conference. Hepg2 cells were transfected using lipofectamine life technologies, cergypontoise, france. Panppar modulation effectively protects appps1 mice from amyloid deposition and cognitive deficits markus p. Dean hum, chief operating officer of genfit, took time out to speak with. Panppar modulation effectively protects appps1 mice from. Ib does not accept short sale orders for us stocks that are not eligible for dtc continuous net settlement cns and all short sale orders are subject to approval by ib. When you upgrade to crunchbase pro, you can access unlimited search results, save your dynamic searches, and get notified when new companies, people, or deals meet your search criteria. Genfit is studying a medicine called elafibranor in patients with stages 23 fibrosis. Dean hum, the coo of genfit, spoke to me about the companys 20year.
Phosphorylation of farnesoid x receptor by protein kinase c promotes its transcriptional activity romain gineste. Metcalf professor of science and engineering at boston university. Gnft has promoted dean hum to president in addition to his duties as chief operating officer. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. Hum, jeancharles fruchart, bart staels, phosphorylation of farnesoid x receptor by protein kinase c promotes its transcriptional. Initiated first phd program in bioinformatics in 1999. Connecting decision makers to a dynamic network of information, people and ideas, bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Sakina sayahjeanne, mathieu dubernet, robert walczak, and dean w. The model used in this study is one of the few experimental models that accurately reproduces the natural.
We have achieved a lot already but what is coming next has the potential to bring the company into a new era of development. Fastest turnaround time in the industry for custom indexes and leader in sri. The transcriptional regulating protein of 2 kda trep2 has been identified in steroidogenic tissues, where it acts as a coactivator of steroidogenic factor 1 sf1. Francque 4, pierre bedossa 5, lawrence serfaty 6, manuel romerogomez 7, paul cales 8, manal f. Mouney or hum would likely have a material adverse effect on us. Joerg schild 5, ari waisman 2, detlef schuppan 1,6. Matthew albert is an immunologist and clinical pathologist, with a longstanding interest in immune regulation and tumor immunity. Fxr is activated by bile acids bas, such as the primary ba chenodeoxycholic acid cdca, which is the most potent ba ligand for the human fxr. Hum, who joined genfit in 2000 as chief scientific officer will be. Dean hum, chief operating officer of genfit, took time out to speak with biospace about the company, the ipo and elafibranor. This availability information regarding shortable stocks is indicative only and is subject to change. Panppar modulation effectively protects appps1 mice from amyloid deposition and cognitive deficits. Top kodi archive and support file community software vintage software apk msdos cdrom software cdrom software. Dr hum, who joined genfit in 2000 as chief scientific officer, will be.
Trep2 controls cell proliferation by regulating the. Snetwork is a publisher of custom indexes and smart beta indexes. Dean hum, the coo of genfit, spoke to me about the companys 20year journey. Frances nash contender genfit leaps onto nasdaq with. New target validation has always been a challenge for the pharmaceutical industry with respect to the potential therapeutic value. Gnft a latestage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, today announced dr. Genfit promotes dean hum to president as it preps us. Dean hum, phd, chief scientific officer of genfit since 2000, has been appointed deputy ceo. The dual peroxisome proliferatoractivated receptor alpha. The digital pathology associations annual conference october,manchester grand hyatt,san diego, ca. Panppar modulation effectively protects appps1 mice from amyloid deposition and.
1194 303 1579 577 617 307 516 26 200 331 318 683 1377 371 1127 1505 1628 1569 1250 1379 245 311 68 349 630 1213 1170 1055 865 1421 897 473 1021